Objective:To study the pharmacokinetic mutual influence between Sanchi extract and Rhizoma coptis extract of Notoginsenoside R1、 Ginsenoside Rg1、 Ginsenoside Rb1 and Berberine,and provide reference for the clinical application of the components of new drugs.Methods:Solid phase extraction were used to pre-treatment of plasma samples,the rate of notoginsenoside Ri、 ginsenoside Rg1 、 ginsenoside Rb1 and berberine as indicators,We were established to determine active ingredients plasma concentration of Sanchi extract and Rhizoma coptis extract single-use and compatibility combined by HPLC.The pharmacokinetic parameters were calculated by DAS3.1.1 pharmacokinetic software and the statistical analysis by SPSS16.0 which reveals the pharmacokinetic variation;Ethyl acetate liquid-liquid extraction method were used to pre-treatment of tissue samples,the rate of notoginsenoside R1.ginsenoside Rg1.ginsenoside Rbi and berberine as indicators,We were established to determine active ingredients tissue concentration of Sanchi extract and Rhizoma coptis extract single-use and compatibility combined by HPLC which research the tissue distribution characteristics.Results:In plasma,the linear range of notoginsenoside Ri,ginsenoside Rgl,ginsenoside Rb1 and berberine is 0.003000mg/L~10.30mg/L,0.005000mg/L~21.51mg/L,0.1160mg/L~466.2mg/L and 0.001960mg/L~2.007mg/L,relative standard deviations(RSD) of the relative recovery and absolute recovery,accuracy,precision and stability experiments of active ingredients of low,medium and high concentration are consistent with the requirements of biological sample analysis;After oral administration,the disposition process of active ingredients of Sanchi extract and Rhizoma coptis extract single-use and compatibility combined in rats could be described by open two-compartment model.Compared to Sanchi extract single-use,significant differences were found on the pharmacokinetic parameters of tl/2a,tl/2p,tl/2Ka,AUC(O-oo),Cmax of notoginsenoside R1,significant differences were found on the pharmacokinetic parameters of t1/2β,AUC(O-t),AUC(O-oo),Cmax of ginsenoside Rgi,significant differences were found on the pharmacokinetic parameters oftl/2a,t1/2p,AUC(O-t),AUC(O-co),Cmax of ginsenoside Rbl,The peak time faster,the peak concentration increase and the bioavailability improve of notoginsenoside Ri.ginsenoside Rgi and ginsenoside Rbi after the compatibility of Sanchi extract and Rhizoma coptis extract;the disposition process of berberine of Rhizoma coptis extract and Sanchi extract single-use and compatibility combined in rats could be described by open two-compartment model.Compared to Coptis extract single-use,significant differences were found on the pharmacokinetic parameters of t1/2a,t1/2Ka,t1/2Ka,AUC(O-oo),Cmax of berberine,after the compatibility of Sanchi extract and Rhizoma coptis extract,Sanchi extract had impossibly improve the absorption and bioavailability of berberine.In tissue,the linear range of notoginsenoside Ri,ginsenoside Rg1,ginsenoside Rbi and berberine is 0.001030mg/L~20.60mg/L,0.001075mg/L~21.51mg/L,0.02331mg/L~233.1mg/L,0.0005881mg/L~11.76mg/L,relative standard deviations(RSD) of the relative recovery and absolute recovery,accuracy,precision and stability experiments of active ingredients of low,medium and high concentration are consistent with the requirements of biological sample analysis;after the compatibility,the concentration of notoginsenoside Ri,ginsenoside Rgl,ginsenoside Rbi and berberine has significantly improved in heart,liver and kidney.Conclusion:There is a pharmacokinetic process mutual influence notoginsenoside R1,ginsenoside Rg1,ginsenoside Rbi and berberine between Sanchi extract and Rhizoma coptis extract,and improve their bioavailability.